

Urinschnelltests (Immunoassays) auf Drogen und Medikamente

Wissenswertes für den Arzt

Recherche de drogues et de médicaments par tests rapides d'urine (immuno-essais)

Informations utiles pour les médecins

Literatur / Références

1. Reisfield GM, Webb FJ, Bertholf RL, Sloan PA, Wilson GR. Family physicians' proficiency in urine drug test interpretation. *J Opioid Manag.* 2007;3(6):333–7.
2. Reisfield GM, Bertholf R, Barkin RL, Webb F, Wilson G. Urine drug test interpretation: what do physicians know? *J Opioid Manag.* 2007;3(2):80–6.
3. George S, Braithwaite RA. Use of on-site testing for drugs of abuse. *Clin Chem.* 2002;48(10):1639–46.
4. Schütz H. Drogenscreening mit Immunoassays. *Pharmazie in unserer Zeit.* 1999;28(6):320–8.
5. Klipfel D, Müller D, Sooth W, Walther A. Leitfaden Drogenerkennung – Drogenvortests und Anfangsverdacht in der Unfallaufnahme und Verkehrsüberwachung, 1st ed. Bonn: Kirschbaum Verlag; 2009.
6. Swiss Guidelines Committee for Drugs of Abuse Testing SCDAT. Richtlinien für die Suchtstoffanalytik (Vers DE 2012–11–15). [cited 2012 Dez 10]. Available from: www.scdat.ch.
7. Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. *Mayo Clin Proc.* 2008;83(1):66–76.
8. Standbridge JB, Adams SM, Zotos AP. Urine drug screening: a valuable office procedure. [Am Fam Physician.](#) 2010;81(5):635–40.
9. Vincent EC, Zebelman A, Goodwin C. What common substances can cause false positives on urine screens for drugs of abuse? *J Fam Pract.* 2006;55(10): 893–4, 897.
10. Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. *Am J Health Syst Pharm.* 2010;67(16):1344–50.
11. Schütz H, Paine A, Erdmann F, Weiler G, Verhoff MA. Immunoassays for drug screening in urine: chances, challenges, and pitfalls. *Forensic Sci Med Pathol.* 2006;2(2):75–83.
12. Schwartz, RH. Urine testing in the detection of drugs of abuse. *Arch Intern Med.* 1988;148(11):2407–12.
13. Tenore PL. Advanced urine toxicology testing. *J Addict Dis.* 2010;29(4):436–48.
14. Jaffee WB, Trucco E, Levy S, Weiss RD. Is the urine really negative? A systematic review of tampering methods in urine drug screening and testing. [J Subst Abuse Treat.](#) 2007;33(1):33–42.
15. Skopp G, Pötsch L, Becker J, Röhrich J, Mattern R. Zur präanalytischen Phase chemisch-toxikologischer Untersuchungen – I. Immunochemisches Drogenscreening im Urin – Erkennbarkeit von Manipulationen und Strategien bei rechtsmedizinischer Fragestellung. *Rechtsmedizin.* 1998;8:163–7.
16. Schwarzhoff R, Cody JT. The effects of adulterating agents on FPIA analysis of urine for drugs of abuse. *J Anal Toxicol.* 1993;17(1):14–7.
17. Morland J, Bugge A, Skuterud B, Steen A, Wethe GH, Kjeldsen T. Cannabinoids in blood and urine after passive inhalation of cannabis smoke. *J Forensic Sci.* 1985;30(4):997–1002.
18. Perez-Reyes M, Di Guiseppi S, Mason AP, Davis KH. Passive inhalation of marijuana smoke and urinary excretion of cannabinoids. *Clin Pharmacol Ther.* 1983;34(1):36–41.
19. Law B, Mason PA, Moffat AC, King LJ, Marks V. Passive inhalation of cannabis smoke. *J Pharm Pharmacol.* 1984;36(9): 578–81.
20. Cone EJ, Johnson RE, Darwin WD, Yousefnejad D, Mell LD, Paul BD et al. Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol. *J Anal Toxicol.* 1987;11(3): 89–96.

21. Cone EJ, Johnson RE. Contact highs and urinary cannabinoid excretion after passive exposure to marijuana smoke. *Clin Pharmacol Ther.* 1986;40(3):247–56.
22. Magerl H, Wiegand C, Schulz E. Cannabinoid intake by passive smoking. *Arch Kriminol.* 1987;179(1–2):31–7.
23. Westin AA, Slordal L. Passive inhalation of cannabis smoke – is it detectable? *Tidsskr Nor Laegeforen.* 2009;129(2):109–13.
24. Schimmel I, Drobnik S, Röhrich J, Becker J, Zörntlein S, Urban R. Passive Cannabisexposition unter realistischen Bedingungen – Untersuchungen in einem Coffee-Shop. *Blutalkohol.* 2010;47:269–74.
25. Toennes SW, Röhrich J, Wunder C. Interpretation of blood analysis data found after passive exposure to cannabis. *Arch Kriminol.* 2010;225(3–4):90–8.
26. George S, Parmar S, Meadway C, Braithwaite RA. Application and validation of a urinary methadone metabolite (EDDP) immunoassay to monitor methadone compliance. *Ann Clin Biochem.* 2000;37:350–4.
27. Larson ME, Richards TM. Quantification of a methadone metabolite (EDDP) in urine: assessment of compliance. *Clin Med Res.* 2009;7(4): 134–41.
28. Rohrig TP, Moore C. The determination of morphine in urine and oral fluid following ingestion of poppy seeds. *J Anal Toxicol.* 2003; 27(7):449–52.
29. Lachenmeier DW, Sproll C, Musshoff F. Poppy seed foods and opiate drug testing – where are we today? *Ther Drug Monit.* 2010;32(1):1–18.
30. Jankovicova K, Ulbrich P, Fuknova M. Effect of poppy seed consumption on the positive results of opiates screening in biological samples. *Leg Med (Tokyo).* 2009;11(Suppl 1):S416–8.
31. Moeller MR, Hammer K, Engel O. Poppy seed consumption and toxicological analysis of blood and urine samples. *Forensic Sci Int.* 2004;143:183–6.
32. Berghaus G, Musshoff F, Madea B. *Verkehrsmedizin – Fahreignung, Fahrsicherheit, Unfallrekonstruktion.* 1st edition. Köln: Deutscher Ärzte-Verlag GmbH; 2007.